

Peer Review File

Article Information: <https://dx.doi.org/10.21037/amj-23-5>

Reviewer A

The review of the status of probes for fluorescence guided surgery is inaccurate. For example, SGM-101 is currently in Phase III clinical trials, but is reported to be used pre-clinically. Minimal information and citations and provided about each of the topic areas and thus the review/editorial is far from capturing the current status of the field.

Thank you for these valuable comments. Please find below the revisions we performed in response to the comments:

- 1- We reviewed the dye section to more accurately reflect the current status of dyes in the market along with their stage of investigation, particularly SGM-101. (Citations and description updated in page 1, lines 37-39)
- 2- We also made sure to include more granular information about the dyes evaluated along with additional citations. We opted not to go into great depth about each of the presented dyes but rather increase the number of dyes we describe with the necessary citations for whoever chooses to read the full associated trials. For example, we added Pantimumab in page 1, line 39-40. Citations were added on page 1 line 39, page 1 line 40, page 2 lines 51-52, page 2 lines 71 and 76
- 3- We added a section on normal tissue dyes to describe another novel group of dyes on page 2 lines 48-52.
- 4- To further elaborate on imaging, we added a section on the use of the exoscope on page 2 line 70-71. Another section on the newer robotic imaging technologies and their applications was added on page 2, lines 72-76.

Reviewer B

A clear objective statement of this editorial at the very beginning would be great.

The editorial is very concise and informative. I love reading it. Would the authors also kindly share more their reflections on areas under development based on clinical scenarios?

Thank you for these valuable comments. Please find below the revisions we performed in response to the comments:

- 1- We added a clear objective statement at the end of the introduction (page 1, line 20-24)
- 2- We added a section in the last paragraph summarizing novel technologies and future directions of every arm described in this editorial.
 - a. Future direction of dyes page 3, lines 109-110
 - b. Future direction of imaging modalities on page 3, lines 111-113
 - c. Future direction of IMI patient selection on page 3, lines 113-115
- 3- We described the strength of the current imaging modalities in identifying disease and extrapolate on its potential use in localizing positive nodes. (Pages 2-3, lines 90-92)
- 4- As far as dye development, we added a section that focuses on novel dyes that are under development and described dyes that are currently in earlier stages of their clinical trials. (Page 1-2, lines 44-47) and page 2(lines 48-52).